228 filings
Page 3 of 12
8-K
7o61m7rekmkiue
12 Feb 21
Entry into a Material Definitive Agreement
8:00am
8-K
osrgqsx r4
14 Jan 21
Other Events
8:13am
8-K
z9qz9xoghr
18 Dec 20
Entry into a Material Definitive Agreement
4:23pm
8-K
yvt1 73s1j0
11 Dec 20
Lexicon Announces Offering of Common Stock
5:28pm
8-K
lpg237ynbrfc7
11 Dec 20
Lexicon Pharmaceuticals Receives Fast Track Designation from the Fda for LX9211 for Diabetic Peripheral Neuropathic Pain
7:43am
8-K
2mtmx zt8zdi2bg9k6wk
17 Nov 20
Results from Soloist and Scored Outcomes Studies
7:22am
8-K
xclqb32n
29 Oct 20
Lexicon Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Clinical Update
7:02am
8-K
i64wb
22 Oct 20
Entry into a Material Definitive Agreement
7:12am
8-K
g6sbwdkvjai356lub7ub
29 Sep 20
Unregistered Sales of Equity Securities
7:14am
8-K
8rtaurbg78n7 myi9
24 Sep 20
Unregistered Sales of Equity Securities
7:12am
8-K
7uypfl
11 Sep 20
Lexicon Pharmaceuticals Completes the Sale of Xermelo to
4:11pm
8-K
ofev5v ed4fb
8 Sep 20
Termination of a Material Definitive Agreement
5:02pm
8-K
v3n giiha
4 Aug 20
Cost Associated with Exit or Disposal Activities
12:00am
8-K
2ikge
30 Jul 20
Lexicon Pharmaceuticals Enters into Agreement
7:18am
8-K
jfakclb 49ikorw
30 Jul 20
Lexicon Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides a Business Update
7:04am
8-K
f8l 0u6wb
15 Jul 20
Entry into a Material Definitive Agreement
5:06pm
8-K
0249ca2tjkd gp
29 May 20
Termination of a Material Definitive Agreement
4:33pm
8-K
i71gnwy8
27 Apr 20
Entry into a Material Definitive Agreement
4:03pm
8-K
l9ylsb2b
27 Apr 20
Lexicon Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides a Business Update
7:04am
8-K
1awks0pz32gnxd ec
12 Mar 20
Lexicon Pharmaceuticals Reports Fourth Quarter and Full-year 2019 Financial Results and Provides a Business Update
7:04am